Mabwell
Manufacturing · China · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
Building 3 Creation Park No. 576 Li Bing...Phone Number
+86 2158585793Website
www.mabwell.comRevenue
$34.5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Mabwell
Mabwell, a values-based, R&D-driven biopharmaceutical company with more than 10 biologics pipelines focuses its efforts on five therapeutic areas: immunology, oncology, metabolic diseases, ophthalmology, and infectious diseases. Mabwell has built a world-class, state-of-the-art R&D engine that includes a high-throughput screening platform for new molecular discovery of hybridoma antibodies, B cell screening platform, ADC drug development platform, PEGylation technology platform, and bispecific antibody development platform. The company has a thriving team of biopharmaceutical scientists across drug discovery, development, manufacture, and commercialization.Explore more
Mabwell Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mabwell your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Mabwell had a recent Job posting/layoffs
Product Launch: Get notified when Mabwell launches new products
Earning: See what the market has to say on Mabwell recently announced quarterly report
Mabwell, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Mabwell has recently received funding, and reach out quickly before it becomes old news!
Check out if Mabwell is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Mabwell
Funding: Get notified immidiatlly once Mabwell has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Mabwell is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mabwell is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mabwell.
Mabwell financials insights
Gather financial insights about Mabwell, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series A
$278M
2022
Stock Offering
$547.9M
Mabwell Tech Stack
A closer look at the technologies used by Mabwell
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Pharmaceuticals, Regulations
Project
Product Development, Legal Affairs, Medical Research, Pharmaceuticals, Regulations
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Project
Product Development, Product Management, Medical Education & Training, Medical Research, Pharmaceuticals, Clinical Operations
Event
Product Marketing, Events, Training, Sales, Logistics / Supply Chain, Pharmaceuticals, Clinical Operations, Field Marketing, Manufacturing Operations, Operations
Mabwell News & Media
Second PIC/S GMP Certification | Mabwell Passes Brazilian GMP Inspection for Its Denosumab Injections
SHANGHAI, Aug. 10, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces that its wholly-owned subsidiary T-mab has successfully passed Brazilian Health Regulatory Agency's ("ANVISA") GMP on-site inspection for its denosumab biosimilars, 9MW0311 (Prolia® biosimilar) and 9MW0321 (Xgeva® biosimilar). This is Mabwell's second GMP certification from a Pharmaceutical Inspection Co-operation Scheme (PIC/S) mESMO 2026 | Mabwell to Present Latest Clinical Data on Nectin-4-targeting ADC 9MW2821 for Triple Negative Breast Cancer in Oral Presentation
SHANGHAI, July 21, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present the latest clinical study results of its novel Nectin‑4‑targeting ADC, 9MW2821, for triple‑negative breast cancer in an oral presentation at the 2026 European Society for Medical Oncology (ESMO) Annual Congress in Madrid, Spain, October 23-27, 2026. Oral Presentation Title: Bulumtatug Fuvedotin (BFv, 9MW2821), a Nectin-4-DirectMabwell Receives IND Clearance from NMPA for LILRB4/CD3-targeting TCE Bispecific Antibody 6MW5311
SHANGHAI, June 23, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) of China has cleared the clinical trial application for its...Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin,...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mabwell
Sign Up For FreeTo access detailed company insights
Mabwell, a values-based, R&D-driven biopharmaceutical company with more than 10 biologics pipelines focuses its efforts on five therapeutic areas: immunology, oncology, metabolic diseases, ophthalmology, and infectious diseases. Mabwell has built a world-class, state-of-the-art R&D engine that includes a high-throughput screening platform for new m... Read More
